Repligen to Report First Quarter 2021 Financial Results
Repligen Corporation (NASDAQ:RGEN) will report its Q1 2021 financial results on May 4, 2021, with a press release issued before market opening. A conference call will be held at 8:30 a.m. EDT to discuss the results for the three-month period ending March 31, 2021. Callers can join via toll-free numbers for domestic and international participants, with no passcode required. The event will also be available for replay. As a leading life sciences company, Repligen specializes in innovative bioprocessing technologies aimed at enhancing biopharmaceutical manufacturing efficiency.
- None.
- None.
Webcast and Conference Call to Be Held Tuesday, May 4, 2021 at 8:30 a.m. EDT
WALTHAM, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2021 financial results on Tuesday, May 4, 2021. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three-month reporting period ended March 31, 2021.
The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the U.S., (855) 669-9658 for callers in Canada and (412) 317-0088 for international callers. Replay listeners must provide the passcode 10155233.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located in the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, Germany, Ireland, the Netherlands and Sweden.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com
FAQ
When will Repligen Corporation announce its Q1 2021 earnings results?
What time is the Repligen conference call scheduled for?
How can I access the Repligen Q1 2021 financial results webcast?
What is the ticker symbol for Repligen Corporation?
